# Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

> **NCT00060671** · PHASE3 · TERMINATED · sponsor: **CTI BioPharma** · enrollment: 800 (—)

## Conditions studied

- Lymphoma, Follicular
- Lymphoma, Mixed-Cell, Follicular
- Lymphoma, Small Cleaved-Cell, Follicular
- Lymphoma, Low-Grade

## Interventions

- **DRUG:** rituximab
- **DRUG:** Pixantrone (BBR 2778)

## Key facts

- **NCT ID:** NCT00060671
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-01
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 800 (—)
- **Last updated:** 2015-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00060671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00060671, "Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00060671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*